THESEUS PHARMACEUTICALS INC (THRX) Stock Price & Overview
NASDAQ:THRX • US88369M1018
Current stock price
The current stock price of THRX is 4.06 USD. Today THRX is down by 0%. In the past month the price increased by 1.75%. In the past year, price decreased by -64.45%.
THRX Key Statistics
- Market Cap
- 181.279M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.34
- Dividend Yield
- N/A
THRX Stock Performance
THRX Stock Chart
THRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to THRX. When comparing the yearly performance of all stocks, THRX is a bad performer in the overall market: 86.76% of all stocks are doing better.
THRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THRX. THRX has a great financial health rating, but its profitability evaluates not so good.
THRX Earnings
THRX Forecast & Estimates
9 analysts have analysed THRX and the average price target is 5.36 USD. This implies a price increase of 31.9% is expected in the next year compared to the current price of 4.06.
THRX Groups
Sector & Classification
THRX Financial Highlights
Over the last trailing twelve months THRX reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS decreased by -12.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.13% | ||
| ROE | -25.22% | ||
| Debt/Equity | 0 |
THRX Ownership
THRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.88 | 901.088B | ||
| JNJ | JOHNSON & JOHNSON | 20.47 | 581.222B | ||
| MRK | MERCK & CO. INC. | 23.46 | 303.313B | ||
| PFE | PFIZER INC | 9.02 | 154.837B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.26 | 121.109B | ||
| ZTS | ZOETIS INC | 16.65 | 50.651B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.27 | 27.862B | ||
| VTRS | VIATRIS INC | 5.37 | 15.67B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 11.664B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.151B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.797B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.066B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.73 | 4.494B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About THRX
Company Profile
Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-10-07. The company is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. The company is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.
Company Info
IPO: 2021-10-07
THESEUS PHARMACEUTICALS INC
314 Main Street, Suite 04-200
Cambridge MASSACHUSETTS 94080 US
CEO: Michael W. Aguiar
Employees: 38
Phone: 18574009491
THESEUS PHARMACEUTICALS INC / THRX FAQ
What does THESEUS PHARMACEUTICALS INC do?
Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-10-07. The company is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. The company is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.
What is the current price of THRX stock?
The current stock price of THRX is 4.06 USD.
What is the dividend status of THESEUS PHARMACEUTICALS INC?
THRX does not pay a dividend.
How is the ChartMill rating for THESEUS PHARMACEUTICALS INC?
THRX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is THESEUS PHARMACEUTICALS INC (THRX) stock traded?
THRX stock is listed on the Nasdaq exchange.
Can you provide the number of employees for THESEUS PHARMACEUTICALS INC?
THESEUS PHARMACEUTICALS INC (THRX) currently has 38 employees.